文献速递中枢神经肿瘤放疗

阿利塞替尼联合同步分次立体定向再照射治疗复发高级别胶质瘤的Ⅰ期试验

Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas.
PubMed 文献 · Radiother Oncol · 2019-01-04

该Ⅰ期试验纳入17例复发高级别胶质瘤成人患者,自2015年2月至2017年2月入组,接受同步分次立体定向再照射(中位剂量35 Gy)联合阿利塞替尼(20至50 mg每日两次递增)及维持治疗。结论认为该方案安全且耐受良好,剂量可达40 mg每日两次,但50 mg队列未完全入组、最大耐受剂量未达到,临床结局似乎与历史结果相当。

要点

  • 同步阿利塞替尼剂量递增至50 mg每日两次,仅观察到1例剂量限制性毒性。
  • 20 mg队列1例重度头痛(3级)经类固醇缓解,无3级及以上非血液学毒性。
  • 50 mg队列未完全入组,最大耐受剂量未达到,试验因阿利塞替尼项目终止而提前停止。

核心结论

  • 分次立体定向再照射联合阿利塞替尼对复发高级别胶质瘤安全且耐受良好,剂量可达40 mg每日两次。
  • 50 mg队列虽未观察到剂量限制性毒性,但该队列未完全入组,最大耐受剂量未达到,临床结局似乎与历史结果相当。

研究设计与样本

  • Ⅰ期试验,纳入复发高级别胶质瘤成人患者,2015年2月至2017年2月入组,共17例。
  • 患者接受同步分次立体定向再照射联合阿利塞替尼,随后阿利塞替尼维持治疗;同步阿利塞替尼剂量从20 mg每日两次递增至50 mg每日两次。

主要发现

  • 中位随访11个月,中位分次立体定向再照射剂量35 Gy。
  • 20 mg、30 mg、40 mg和50 mg队列分别入组6例、6例、3例和2例患者。
  • 仅观察到1例剂量限制性毒性:20 mg队列1例重度头痛(3级)经类固醇缓解;无3级及以上非血液学毒性。
  • 发生2例4级晚期毒性(1例4级中性粒细胞减少和白细胞减少,1例肺栓塞);1例发生放射性坏死(3级)。
  • 16例完成同步治疗并接受维持治疗(中位周期数3,范围1-9);全部队列6个月总生存率为88.2%,中位生存时间11.1个月;6个月无进展生存率为35.3%,中位进展时间4.9个月。

关键数值与推荐

  • 同步阿利塞替尼剂量递增水平为20 mg、30 mg、40 mg和50 mg每日两次。
  • 试验因阿利塞替尼项目终止而提前停止,50 mg队列计划入组3例中仅入组2例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验提前停止:因阿利塞替尼项目终止,50 mg队列计划3例中仅入组2例。
  • 50 mg队列未完全入组,最大耐受剂量未达到。
  • 临床结局似乎与历史结果相当(原文以「appear comparable to historical results」表述)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We conducted a phase I trial of alisertib, an oral aurora kinase inhibitor, with fractionated stereotactic re-irradiation therapy (FSRT) for patients with recurrent high grade glioma (HGG). MATERIALS AND METHODS: Adult patients with recurrent HGG were enrolled from Feb 2015 to Feb 2017. Patients were treated with concurrent FSRT and alisertib followed by maintenance alisertib. Concurrent alisertib dose was escalated from 20 mg to 50 mg twice daily (BID). RESULTS: 17 patients were enrolled. Median follow-up was 11 months. Median FSRT dose was 35 Gy. There were 6, 6, 3, and 2 patients enrolled in 20 mg, 30 mg, 40 mg, and 50 mg cohort, respectively. Only one DLT was observed. One patient in the 20 mg cohort had severe headache (Grade 3) resolved with steroids. There was no non-hematological grade 3 or higher toxicity. There were two Grade 4 late toxicities (one with grade 4 neutropenia and leukopenia, one with pulmonary embolism). One patient developed radiation necrosis (Grade 3). Sixteen patients finished concurrent treatment and received maintenance therapy (median cycles was 3, range 1-9). OS for all cohorts at 6 months was 88.2% with median survival time of 11.1 months. PFS at 6 months was 35.3% with median time to progression of 4.9 months. The trial stopped early due to closure of alisertib program with only 2 of 3 planned patients enrolled in the 50 mg cohort. CONCLUSION: Re-irradiation with FSRT combined with alisertib is safe and well tolerated for HGG with doses up to 40 mg BID. Although no DLT observed in the 50 mg cohort, this cohort was not fully enrolled and MTD was not reached. Clinical outcomes appear comparable to historical results. (NCT02186509).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Song A, Andrews DW, Werner-Wasik M, et al. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. Radiother Oncol. 2019. PMID: 30825962. doi:10.1016/j.radonc.2018.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。